# AMITMED

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amitmed

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: amit.net.cn
- Latest round: Series A (Nov 1, 2024)
- Investors on record: 1

## About

Based in China, AMITMED specializes in advanced medical technology, focusing on minimally invasive surgical solutions through its innovative ultrasound-guided robotic platform system. This technology enhances surgical precision and efficacy.Founded in 2021, AMITMED operates in Beijing, China, where it provides advanced surgical solutions. The company has engaged in 4 deals, with its most recent deal taking place on November 1, 2024. The company has not undergone any notable pivots or changes in operations since its inception.Beijing Aoda Zhisheng Medical Technology Co., Ltd. specializes in advanced minimally invasive surgical solutions, primarily through its ultrasound-guided robotic platform system. This innovative system leverages artificial intelligence and robotics to enhance the precision and efficacy of procedures such as punctures and ablations, thereby minimizing reliance on the surgeon's manual skills and experience. The platform integrates pre-operative planning and intra-operative navigation, offering a comprehensive solution for the entire puncture and ablation process. The end users of these technologies include hospitals and medical facilities that aim to improve surgical outcomes while addressing clinical pain points associated with traditional methods. The company’s products have been designed for the Chinese healthcare market, specifically targeting urban hospitals and surgical centers seeking to adopt technology in interventional procedures.The revenue generation approach for Beijing Aoda Zhisheng Medical Technology Co., Ltd. is primarily focused on B2B transactions with hospitals and medical institutions. The company engages in direct sales of its robotic systems and associated software to healthcare providers, establishing long-term partnerships to facilitate ongoing support and upgrades. Additionally, the company offers training and maintenance services as part of its product suite, ensuring that end users maximize the effectiveness of their purchased technologies. While specific pricing details for the company's flagship products are not disclosed, the revenue model reflects a strategic emphasis on providing comprehensive solutions that enhance surgical efficiency and patient outcomes, thereby reinforcing the value proposition to their client base in the healthcare sector.In November 2024, AMITMED raised an undisclosed amount of Series A funding from new investor Qianhai Ark Asset Management. The company plans to utilize this funding to accelerate the development of new products, specifically targeting enhancements in its robotic systems. AMITMED aims to expand its reach into additional markets, including rural healthcare facilities across China, by 2025. This growth strategy will support the introduction of new technologies designed to improve surgical outcomes and address the needs of diverse healthcare providers.

## Funding rounds

- Series A, Nov 1, 2024 — Qianhai Ark Capital

## Investors

- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series A